Inhibitors of IL-15 and their use in treating Autoimmune/Inflammatory disorders
IL-15 controls the immune system by stimulating T cell proliferation and maintains the function of natural killer (NK) cells and memory T-cells. Using a combinatorial screening technology, our inventors discovered a new compound that is able to bind to and completely inhibit the function of the IL-15 receptor. This compound is named IFRA3. IFRA3 is a Peptoid compound that can be delivered orally for therapeutic purposes. The compound inhibits inflammation and the immune response, it has the potential to become a drug that has a wide range of clinical applications.
Applications
  • Rheumatoid arthritis
  • Systemic lupus erythematosus (SLE)
  • Crohn disease
  • Multiple Sclerosis
Problems Addressed
  • Current therapy for Rheumatoid Arthritis (RA) includes Methotrexate (MTX) which achieves a significant clinical Response in only 28% of the patients.
  • Humira is often used in combination with MTX. However, the combination only achieves significant clinical response rate of just 49%.
Competitive Advantages
  • Affordable and simple to synthesize.
  • Oral dosage.
  • Could be used in combination with current treatment strategies.
  • No stringent storage conditions required compared to antibodies. 
  • Protease resistant, hence more resistant to systemic degradation compared to antibodies.
Patents

62/870,318

Case ID
2019-052
Inventor
Bin Guo
Associate Professor, Department of Pharmacy